Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
about
Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in ParkinsonĀ“s disease patients with motor complicationsCatechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's diseaseCarbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's diseaseLevodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.Dopaminergic substitution in Parkinson's disease.Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.Deep brain stimulation for early-stage Parkinson's disease: an illustrative case.Novel pharmacological strategies for motor complications in Parkinson's disease.Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.Current status of symptomatic medical therapy in Parkinson's diseaseEvidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation.Levodopa in the treatment of Parkinson's disease: an old drug still going strong.Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease.Patient diaries as a clinical endpoint in Parkinson's disease clinical trials.Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.Improving L-dopa therapy: the development of enzyme inhibitors.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.A review of current and novel levodopa formulations for the treatment of Parkinson's disease.Opicapone for the treatment of Parkinson's disease.Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective.Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.Association Between Catechol-O-Methyltransferase (COMT) Gene Polymorphisms, Parkinson's Disease, and Levodopa Efficacy.Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.Levodopa/carbidopa/entacapone in Parkinson's disease.Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of tradiShould levodopa dose be reduced when switched to stalevo?Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison.Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis.
P2860
Q24234273-FF3187A1-4E09-4DEF-8063-4A54C8E034D4Q24245911-D8A2C2CB-307A-4EC7-A5FF-2151B61EC131Q34041790-A67C4F2B-A487-4206-AFEB-26CC0FC28AEAQ34593590-88C3686F-13AF-428E-89BF-D82D25C0F29CQ34974788-4B64EB52-0792-436B-89CF-0A48FCF1FAFCQ35194383-E78159FA-E6E6-4791-95DD-05BF2713B99EQ35613111-07587742-1D4A-4B17-A406-EAC5305574B3Q36120761-E25236DC-F82C-4E4E-80AD-5AF6132BFDF0Q36278049-EEB03AA5-1FDF-497C-9B06-D3E785A75049Q36521884-83F4F7E9-BF83-4744-A918-CD5219007D97Q37131229-127C8CD1-8788-4212-9F0E-035089A2893BQ37164701-490ACFC4-CC9D-476E-A971-C76D6E1593F6Q37544096-46EE31C5-CFEC-4E9C-A109-C4F5720F58DEQ37790274-17361366-E1AC-4723-955A-B50BC0C11E03Q37849251-A1379994-DCBE-453D-97F6-CD02A57F4537Q37954392-2A869710-8AD4-4579-94A2-7A4A55570CA4Q37979869-94010567-3E9C-448F-AD72-0F4D025C282EQ38223072-D09DC817-1BD2-46F0-9933-EC1EC12EDE5FQ38261811-ABE16477-8F91-47F3-A871-169EA77A096EQ38262418-1D8FCAEE-4D21-4DE9-896B-92799F9E6F81Q38361898-0153D6E5-4DD9-4D69-AE1C-2C97C9368202Q38740274-FBF8B5D9-792F-4A73-970C-C41F71074F1EQ38943872-3D30B519-E227-4E9C-8E00-25E369447A2DQ38947463-253CB778-B8DC-401F-91AD-63133AE022D1Q42392773-A620ED38-EA8D-4335-8136-DEA32DD21503Q42427666-05EB2258-9173-4C0D-BA65-AFA81717272DQ42626399-7AF5E04F-93A5-48D8-B8CD-8C0AD806F9A8Q42644898-4AFE4EE1-8A85-4FA3-A354-4EAB443F10BBQ43662733-53AA6A9D-7DB0-4A0A-BE8D-45998AB2A71DQ45075694-C825E68E-4CAC-456A-B443-631B67F1F1ACQ45185102-8A4A4268-DB75-4E49-B423-8E604D205DE6Q45772315-E4922FF1-9C0F-4C44-A89E-72B7FFB5D50DQ45934197-D98EE845-1E40-459E-A3B3-046EA940C534Q46119482-5B414B79-C40E-4EE7-939D-1DD6D63548ABQ46560454-0F0039CA-B077-4C03-8ECB-7883F01F9CE3Q46794730-AA381517-9C26-4395-BF3D-E60F60862AA0Q48129862-0114C89A-44EB-4228-B229-2C3D43F42F48Q48175839-52BB0227-4A8F-493E-BA95-02F329CE6E46Q50502365-BAE63C38-2147-4AB4-82D4-666A98748467
P2860
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
description
2002 nĆ® lÅ«n-bĆ»n
@nan
2002幓ć®č«ę
@ja
2002幓å¦ęÆęē«
@wuu
2002幓å¦ęÆęē«
@zh-cn
2002幓å¦ęÆęē«
@zh-hans
2002幓å¦ęÆęē«
@zh-my
2002幓å¦ęÆęē«
@zh-sg
2002幓åøč”ęē«
@yue
2002幓åøč”ęē«
@zh
2002幓åøč”ęē«
@zh-hant
name
Efficacy and safety of entacap ...... y and Austria (Celomen study).
@en
Efficacy and safety of entacap ...... d study in Germany and Austria
@nl
type
label
Efficacy and safety of entacap ...... y and Austria (Celomen study).
@en
Efficacy and safety of entacap ...... d study in Germany and Austria
@nl
prefLabel
Efficacy and safety of entacap ...... y and Austria (Celomen study).
@en
Efficacy and safety of entacap ...... d study in Germany and Austria
@nl
P2093
P2860
P921
P1476
Efficacy and safety of entacap ...... y and Austria (Celomen study).
@en
P2093
Celomen Study Group
E-R Kultalahti
M Leinonen
P2860
P304
P356
10.1034/J.1600-0404.2002.1O174.X
P407
P577
2002-04-01T00:00:00Z